It has been another busy week for many of Australia's top brokers. This has led to the release of a number of broker notes.
Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone right now:
Life360 Inc. (ASX: 360)
According to a note out of Morgan Stanley, its analysts have retained their overweight rating on this location technology company's shares with an improved price target of $58.50. Morgan Stanley was impressed with the company's performance during the second quarter and was pleased to see yet another earnings guidance upgrade. Morgan Stanley believes Life360's positive form can continue thanks to strong subscriber growth and increased user monetisation. Outside this, the broker feels investors are underappreciating Life360's opportunity outside its core market. This includes the millions of pet owners that could be interested in its pet tracking service. The Life360 share price is trading at $52.75 this afternoon.
Premier Investments Ltd (ASX: PMV)
A note out of Ord Minnett reveals that its analysts have retained their buy rating on this retail conglomerate's shares with an improved price target of $23.40. This follows the release of its FY 2025 results. Although the Peter Alexander and Smiggle owner's earnings and outlook statement were a touch short of expectations and there are concerns about its structure and the lack of a permanent CEO, it remains positive. Especially with its shares trading at a meaningful discount to retail peers. The Premier Investments share price is fetching $19.74 at the time of writing.
Telix Pharmaceuticals Ltd (ASX: TLX)
Analysts at Bell Potter have retained their buy rating and $23.00 price target on this radiopharmaceuticals company's shares. According to the note, the broker was pleased to see some good news finally come out of the company after a series of blows from the US FDA. This news revealed that the US CMS has granted pass through pricing for Gozellix from 1 October. Bell Potter believes that the decision to pursue this strategy has proven to be a master stroke by the company and shown its major competitor in the PSMA imaging market is asleep at the wheel. Outside this, the broker remains positive due to its belief that the manufacturing matters blocking the approval of other products can be resolved expeditiously. The Telix share price is trading at $14.99 on Friday.
